论文部分内容阅读
目的研究患者肺癌组织中P-选择素、组织蛋白酶D(CD)的表达,进而探讨它们与肺癌临床病理的关系。方法采用免疫组化法检测58例患者肺癌组织中P-选择素、组织蛋白酶D的表达水平。结果 P-选择素和CD在肺癌组织中的阳性率分别为43.1%(25/58)和53.5%(31/58),P-选择素与淋巴结转移有关(P﹤0.05),与病理类型、病理分级、病理分期、5年存活率无关(P﹥0.05)。CD表达与病理分期、淋巴结转移、5年存活率有关(P﹤0.05),与病理类型、病理分级无关(P﹥0.05)。两个指标均表达阳性的肺癌患者5年存活率为31.3%(5/16),显著低于阴性患者5年存活率81.8%(9/11),P﹤0.05。结论共同检测P-选择素和CD水平,对于判断肺癌患者的预后有重要意义。
Objective To study the expression of P-selectin and cathepsin D (CD) in lung cancer and to explore their relationship with the clinicopathological features of lung cancer. Methods Immunohistochemistry was used to detect the expression of P-selectin and cathepsin D in 58 cases of lung cancer. Results The positive rates of P-selectin and CD in lung cancer were 43.1% (25/58) and 53.5% (31/58), respectively. P-selectin was associated with lymph node metastasis (P <0.05) Pathological grade, pathological stage, 5-year survival rate was not related (P> 0.05). The expression of CD was correlated with the pathological stage, lymph node metastasis and 5-year survival rate (P <0.05), but not with pathological type and pathological grade (P> 0.05). The 5-year survival rate was 31.3% (5/16) in patients with lung cancer positive for both indicators, which was significantly lower than that in negative patients (81.8%, 9/11) (P <0.05). Conclusions Co-detection of P-selectin and CD levels is of great importance in judging the prognosis of patients with lung cancer.